Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials
Authors:
- Vibeke StrandVibeke Strand
- Dinesh KhannaDKDinesh Khanna
- Jasvinder A. SinghJasvinder A. Singh
- Anna ForsytheAFAnna Forsythe
- N. Lawrence EdwardsNEN. Lawrence Edwards
Open Access
- 1 June 2012
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (7) , 1450-1457
Abstract
Objective.: To assess the efficacy of pegloticase on pain, physical function, and health-related quality of life (HRQOL) in patients with refractory chronic gout.Methods.: Subjects in 2 replicate, 6-month, randomized controlled phase III trials received intravenous infusions of pegloticase 8 mg twice monthly (biweekly group), pegloticase alternating with placebo (8-mg monthly group), or placebo. Medical Outcomes Study Short Form-36 (SF-36), Health Assessment Questionnaire-Disability Index (HAQ-DI), patient global assessment of disease activity (PtGA), and pain by visual analog scale were completed at weeks 1 (baseline), 13, 19, and 25. Prespecified pooled analyses of patient-reported outcomes were performed by combining values for each treatment group (biweekly treatment, monthly treatment, and placebo) at Week 25.Results.: Of 212 patients enrolled, 157 (74.1%) completed treatment. At entry, mean age was 55.4 years (range 23–89 yrs) and mean plasma uric acid was 9.7 mg/dl; most were male (81.6%) and white (67.5%). Subjects reported an average of 9.8 flares in the previous 18 months. Baseline SF-36 physical component summary (PCS) scores were > 1.5 SD below US normative values. At Week 25, mean changes from baseline in PtGA, pain, HAQ-DI, and PCS scores were statistically significant and exceeded minimum clinically important differences (MCID) in the biweekly treatment group, compared with little to no improvement in placebo group. Statistically significant improvements greater than or equal to MCID were reported in 6 of 8 SF-36 domains. Monthly pegloticase resulted in significantly improved PtGA, HAQ-DI, PCS, and 3 SF-36 domains.Conclusion.: Pegloticase therapy resulted in statistically significant and clinically meaningful improvements in PtGA, pain, physical function, and HRQOL.Keywords
This publication has 24 references indexed in Scilit:
- Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatmentAnnals of the Rheumatic Diseases, 2012
- Gout. Epidemiology of goutArthritis Research & Therapy, 2010
- Newer Biological Agents in Rheumatoid ArthritisDrugs, 2010
- Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia SyndromeThe Journal of Rheumatology, 2009
- Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veteransAnnals of the Rheumatic Diseases, 2008
- Validation of the Health Assessment Questionnaire disability index in patients with goutArthritis Care & Research, 2008
- Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of goutAnnals of the Rheumatic Diseases, 2007
- Using the SF-12 Health Status Measure to Improve Predictions of Medical ExpendituresMedical Care, 2006
- SF-36 Health Survey UpdateSpine, 2000
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976